Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 17/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17898285 | 0.95 | KDM4C (0.36) | KDM4CHRH3 | |
| SCHEMBL17898295 | 0.95 | KDM4C (0.45) | KDM4CHRH3 | |
| SCHEMBL17898303 | 0.87 | KDM4C (0.40) | KDM4CHRH3 | |
| SCHEMBL17898283 | 0.87 | KDM4C (0.40) | KDM4CHRH3 | |
| SCHEMBL17898293 | 0.86 | KDM4C (0.49) | KDM4C | |
| SCHEMBL17898265 | 0.85 | KDM4C (0.46) | KDM4C | |
| SCHEMBL17898279 | 0.84 | KDM4C (0.39) | KDM4CHRH3 | |
| SCHEMBL17898277 | 0.83 | KDM4C (0.43) | KDM4C | |
| SCHEMBL17898297 | 0.83 | KDM4C (0.39) | KDM4CBTK | |
| SCHEMBL17901767 | 0.83 | KDM4C (0.43) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3430008-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-10208039-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10202381-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10030017-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030017-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| WO-2017161012-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | KDM4C 9/4885BTK 2988/4885MCHR1 3089/4885 |
| US-10030017-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | KDM4C 9/4885BTK 2988/4885MCHR1 3089/4885 |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | KDM4C 9/4885BTK 2988/4885MCHR1 3089/4885 |
| US-10202381-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | KDM4C 9/4885BTK 2988/4885MCHR1 3089/4885 |
| US-10208039-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | KDM4C 9/4885BTK 2988/4885MCHR1 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.